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See related research by Frenette et al., http://ccforum.com/content/18/6/602In a previous issue of Critical Care, Frenette and col-
leagues [1] described a retrospective study of 984 cardiac
surgery patients receiving mixed colloids, including
hydroxyethyl starch (HES) 130/0.4 in 82% or HES 200/
0.5 in 43%. In 25% or more of the patients, both HES
solutions were used. A small minority (16%) received 5%
or 25% albumin. An association was observed between
albumin exposure and acute kidney injury (AKI).
Much essential information is not provided, including
what colloids were administered, why, and when. How
many patients received 5% albumin? 25% albumin? How
often was albumin co-administered with HES 130/0.4?
With HES 200/0.5? With both? In what co-administered
doses? How much of each colloid was used for extracor-
poreal circuit priming? For volume expansion? How
much albumin was used to correct hypoalbuminemia?
What was the temporal relationship between albumin
infusion and AKI development?* Correspondence: mwilkes@hygeiaassociates.com
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unless otherwise stated.No serum albumin levels are reported. Yet preopera-
tive hypoalbuminemia is a potent independent risk fac-
tor for renal failure in cardiac surgery patients (adjusted
odds ratio 2.0, 95% confidence interval 1.3 to 3.2) [2]. A
reported 15% of patients come to cardiac surgery with
severe hypoalbuminemia (less than 25 g/L serum albu-
min), and the majority of those (58%) undergo elective
procedures [2].
Albumin is typically reserved for a small minority
of the highest-risk patients [3,4]. That practice may
explain this study. The significantly lower HES 200/0.5
doses co-administered with albumin in the propensity-
matched population suggest that albumin was substituted
to mitigate the increased AKI risk of HES 200/0.5
previously reported by this same team of investigators
[5]. With obvious potential selection bias and many
unanswered questions, this study needs to be interpreted
with caution.illiamsonWe agree with Groeneveld and colleagues that there
are several unanswered questions regarding the use of
albumin. Albumin administration has been associated
with different outcomes depending on the type of
population studied [6-9]. In the recent Albumin Italian
Outcome Sepsis (ALBIOS) trial, administration of 20%
albumin did not improve prognosis by correcting
hypoalbuminemia, improving hemodynamic status, or
restricting the total amount of fluid administered [9]. In
addition, albumin is expensive and may carry an
infectious risk.
In our study, we acknowledged that we could not rule
out residual confounding despite the use of a propensityscore analysis and mentioned that we did not have data
on serum albumin levels [1]. However, we described the
timing and type of colloids administered and stated that
the vast majority of the surgeries were elective. We
used a propensity score analysis, which included the
percentage and dose of synthetic colloids adminis-
tered, to address any indication bias. However, our
study does not provide a definitive answer on the
administration of albumin in cardiac surgery patients.
As we concluded, we believe that the safety of albumin-
containing fluids on kidney function should be assessed
in future cardiac surgery trials. The administration of a
costly product currently associated with neutral or
potentially negative outcomes in this population needs
to be better delineated.ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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AKI: Acute kidney injury; HES: Hydroxyethyl starch.
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